vamorolone (Pending FDA Approval)

Brand and Other Names:

Dosing & Uses

AdultPediatric

Duchenne Muscular Dystrophy

Pending FDA approval for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Pending FDA approval for Duchenne Muscular Dystrophy

Next:

Pharmacology

Mechanism of Action

First-in-class steroidal anti-inflammatory drug that differs from conventional glucocorticoids by its lack of an 11β hydroxy-carbonyl group

Removal of this contact site with the glucocorticoid receptor significantly alters structure and activity associations

Additionally, unlike glucocorticoids, vamorolone is not a substrate for 11β-hydroxysteroid dehydrogenase regulatory enzymes and is a mineralocorticoid receptor antagonist

It retains subactivities associated with efficacy (transrepression, physicochemical membrane effects, synchronization of tissue remodeling), and dissociates efficacy from other subactivities associated with detrimental side effects

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.